

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Amivantamab for treating EGFR Exon 20 insertion-  
positive non-small-cell lung cancer after platinum-based  
chemotherapy**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes the company raised a potential equality issue because people with EGFR-positive subtypes of non-small cell lung cancer are more likely to be Asian.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

Issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

**Approved by Associate Director (name):** Ross Dent

**Date:** 8/03/21